Bright Minds - A Biotechnology Company in Canada

Recent stats suggest that the market for psychedelic stocks will nearly double in dollar amounts by 2027. It is by far the fastest-growing trade one can experience after cannabis was made legal in the US. That also makes it favorable for early investors...

Addiction to SSRIs is what mental health patients, as well as psychologists, despise. That’s when none of these two parties know how to proceed with the treatment exactly. With numerous nerves just in the central nervous system, many things can go wrong...

Bright Minds Biosciences is a start-up in the field of pharmaceuticals, dealing with neuropsychiatric disorder management through biotechnologically developed drugs. As a biotechnology company , we enforce the ideas and experiences of our experts into...

Trading in psychedelic stocks came to a halt after the ban that the US government imposed. However, the year 2020 saw a major shift in the research industry that studies probable treatments for neurological and mental health disorders. The same year,...

Did you know that the ‘shark’ investor, Mr. Kevin O’Leary was amongst the first business person to invest in psychedelic stocks? Initially, investors thought this investment to be a binary one. However, after the emergence of multiple start-ups that deal...

If any buyers may feel that they were left out of the early boom for a marijuana stock. Don't worry; there's still plenty of space for the weed industry to expand. However, if you're looking to get into a booming new industry, you may want to look into...

Bright Minds Biosciences, by launching their lead product as their main psychedelic stock , the biotechnology company starts a new wave of innovation at improving the effects of drugs such as Psilocybin. The next unicorn for investors on CSE, undoubtedly,...

The future of investing in psychedelic drug stocks looks quite bright. Emerging biotechnology start-ups that re-design psychoactive compounds' molecular structure to reduce trip time and maximize its potential to treat mental health disorders have led...

Psychedelics companies vary in their areas of focus. Many are developing psychedelics-based medications in the hopes of gaining regulatory approval, while others host psychedelic retreats in jurisdictions where they’re legal. Some are working to develop...

Bright Minds a biotechnology company dedicated to developing next-generation therapeutics to improve the lives of patients with severe and life-altering brain diseases. Bright Minds’ broad portfolio of new chemical entities (NCEs) are positioned to treat...